6XP Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Xspray Pharma AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 3.72 |
52 Week High | SEK 7.63 |
52 Week Low | SEK 3.66 |
Beta | 0.84 |
11 Month Change | -30.86% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -36.77% |
Recent News & Updates
Recent updates
Shareholder Returns
6XP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -0.7% | -0.02% |
1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how 6XP performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6XP performed against the German Market.
Price Volatility
6XP volatility | |
---|---|
6XP Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 6XP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6XP's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 24 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
6XP fundamental statistics | |
---|---|
Market cap | €121.11m |
Earnings (TTM) | -€22.44m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs 6XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6XP income statement (TTM) | |
---|---|
Revenue | SEK 0 |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 0 |
Other Expenses | SEK 258.05m |
Earnings | -SEK 258.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) | -7.64 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 6XP perform over the long term?
See historical performance and comparison